bpc-157 fda status 2025 or 2026 Peptide Reclassification 2026: What It Means for Providers FDA panel to consider easing

Many patients can start with telehealth consultations, depending on medical eligibility and state regulations

Hypothetical Dosing Considerations While no evidence-based cagrilintide dosage with retatrutide protocol exists, theoretical frameworks based on monotherapy data suggest several principles that would likely apply: Conservative Approach Principles: Start with minimal doses Perhaps 0.3 mg cagrilintide + 2 mg retatrutide weekly Extended titration periods 16-24 weeks to reach target doses instead of standard 8-12 weeks Alternating escalation Increase one compound while holding the other stable Frequent monitoring Weekly check-ins during initial phases Lower maximum doses Perhaps 1.2 mg cagrilintide + 8 mg retatrutide rather than maximum monotherapy doses These suggestions remain purely speculative and should not be interpreted as clinical recommendations

Craig: It's interesting

So for chronic degenerative conditions, my bias is to avoid it, and my bias strengthens the longer someone wants to use it

The Safety Profile: Are Injections Safe